Aug 28, 2025
Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes
Dec 20, 2024
FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors
Dec 07, 2024
Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease
Sep 06, 2024
Novo Nordisk to present new data from key diabetes and obesity trials at the 60th Annual Meeting of the European Association for the Study of Diabetes
Jun 24, 2024
Ozempic® (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Association
Mar 08, 2024
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Dec 04, 2020
FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
Nov 05, 2020
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
Sep 10, 2020
ACC, Novo Nordisk Partner to Improve Cardiovascular Disease Management in Patients with Type 2 Diabetes
Aug 12, 2020
Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing
Jun 19, 2020
Smart Insulin Pens Market to Exhibit a Revised CAGR of 1.6% During 2019-2020 due to COVID-19 Supply Chain Disruption
Jun 14, 2020
Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial
Jun 11, 2020
Diabetes Care Devices Market Worth $4.3 Billion by 2025 - Exclusive Report by MarketsandMarkets(TM)
Jun 02, 2020
Novo Nordisk to present new data at the 80th Annual American Diabetes Association Scientific Sessions
May 27, 2020
Insulin Market Report 2020: Includes Revenue Data (2013-2022) for Novo Nordisk, Sanofi Aventis, Eli Lilly, Merck & Co, and Beckton Dickinson
Apr 14, 2020
Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
Apr 08, 2020
Global Diabetes Devices Industry Assessment 2020-2027 - Technological Advancements in Diabetes Devices, Rising Awareness About Diabetes Preventive Care
Apr 06, 2020
MAI Construction, Inc. Completes 4-Phase Project for Novo Nordisk in Fremont, California
Apr 02, 2020
Coronavirus (COVID-19) resources available from Novo Nordisk in the US
Mar 31, 2020
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity